Regeneron Stock Surges On Positive Results In Eye Disease Drug Trial

Regeneron stock surges on positive results in eye disease drug trial

Regeneron Up 25% On Positive Phase III Cancer Drug Trial

FinancialNewsOnline

Regeneron reports positive results on initial data for Covid-19 antibody drug

CNBC Television

Our Research and Innovations

Regeneron CEO On The Eye Drug Market | Forbes

The Case For Regeneron's Eye Drug

Regeneron reports antibody drug lowers risk of medical visits by 57%

CNBC Television

Stocks fluctuate, Regeneron stock surges, oil above $83 a barrel

Coronavirus: Regeneron, Sanofi release preliminary results for Kevzara drug trial

CNBC Television

Regeneron Clinical Trials In Colorado Leave Some Optimistic

Regeneron CEO on the prospects for its eye drug Eylea

CNBC Television

Regeneron CEO: We'll likely have to constantly adapt our antibody cocktail

CNBC Television

Reata soars on positive drug trial results

CNBC Television

Intellia soars on trial results using CRISPR technology

CNBC Television

Regeneron aims for COVID-19 drug trials by early summer

CNBC Television

News Update: Regeneron Pharmaceuticals, Inc. to Release Data on Late-Stage Drug Trials

Spectrum Health launches Regeneron COVID-19 study

Our Medicines

Regeneron's science chief on starting clinical trials for Covid-19 antibody drug

CNBC Television

Daily Covid-19 Minute: Regeneron’s Antibody Cocktail